Showing 451-460 of 471 results for "".
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- New Merz Survey Highlights Misconceptions about Tattoo Removalhttps://modernaesthetics.com/news/new-merz-survey-highlights-misconceptions-about-tattoo-removal/2472104/More than four in five adults with (86 percent) and without (82 percent) tattoos have misconceptions about tattoo removal, including confusion regarding side effects, cost and removability, according to a new Merz survey. In addition to not knowing how the process works, many underestimat
- New Line of Laser Systems Now Available from Sensus Healthcarehttps://modernaesthetics.com/news/new-line-of-lasers-systems-now-available-from-sensus-healthcare/2472120/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective lasers for hair and tattoo removal, acne lesion correction, skin rejuvenation and pigmentation/large pore treatment. Prior to this launch, the medical device company specialized
- New AAFPRS Data: Social Media Makes Lasting Impact on Industryhttps://modernaesthetics.com/news/new-aafprs-data-social-media-makes-lasting-impact-on-industry/2472141/Like it or not, the selfie and its impact on aesthetics is here to stay, and continues to have a huge effect on how we perceive and project ourselves in front of the camera and off. This is among the main findings from the annual survey of the
- Allergan CEO Calls for Consensus on Medical Aesthetic Treatment in Minorshttps://modernaesthetics.com/news/allergan-ceo-calls-for-consensus-on-medical-aesthetic-treatment-in-minors/2472213/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Survey: Many Bothered By Double Chins, Take Steps To Cover Uphttps://modernaesthetics.com/news/survey-many-bothered-by-double-chins-take-steps-to-cover-up/2472259/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc.<
- Allergan Agrees to Acquire ZELTIQ for $2.47 Billionhttps://modernaesthetics.com/news/allergan-agrees-to-acquire-zeltiq-for-247-billion/2472280/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- Allergan Launches Juvéderm Volitehttps://modernaesthetics.com/news/allergan-launches-juvderm-volite/2472287/Allergan plc launched Juvéderm Volite, an injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented Vycross technology. The new HA injectable treatment d
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Contributing Editorhttps://modernaesthetics.com/profiles/contributing-editor/7rB8NP/